Page 76 - 51 the significance--29.2_opt
P. 76
42. Bolli G, Dotta F, Rochotte E, Cohen SE. Efficacy and tolerability of vildagliptin vs.
pioglitazone when added to metformin: a 24-week, randomized, double-blind
study. Diabetes, obesity & metabolism 2008;10(1):82-90.
43. Ahren B, Gomis R, Standl E, Mills D, Schweizer A. Twelve- and 52-week efficacy of
the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2
diabetes. Diabetes care 2004;27(12):2874-80.
44. Ferrannini E, Fonseca V, Zinman B, Matthews D, Ahren B, Byiers S, et al. Fifty-two-
week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 dia-
betes mellitus inadequately controlled on metformin monotherapy. Diabetes,
obesity & metabolism 2009;11(2):157-66.
45. Garber AJ, Schweizer A, Baron MA, Rochotte E, Dejager S. Vildagliptin in combination
with pioglitazone improves glycaemic control in patients with type 2 diabetes failing
thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes,
obesity & metabolism 2007;9(2):166-74.
46. Garber AJ, Foley JE, Banerji MA, Ebeling P, Gudbjornsdottir S, Camisasca RP, et al.
Effects of vildagliptin on glucose control in patients with type 2 diabetes inade-
quately controlled with a sulphonylurea. Diabetes, obesity & metabolism 2008;
10(11):1047-56.
47. Rosenstock J, Aguilar-Salinas C, Klein E, Nepal S, List J, Chen R. Effect of saxagliptin
monotherapy in treatment-naive patients with type 2 diabetes. Current medical
research and opinion 2009;25(10):2401-11.
48. Jadzinsky M, Pfutzner A, Paz-Pacheco E, Xu Z, Allen E, Chen R. Saxagliptin given in
combination with metformin as initial therapy improves glycaemic control in
patients with type 2 diabetes compared with either monotherapy: a randomized
controlled trial. Diabetes, obesity & metabolism 2009;11(6):611-22.
49. DeFronzo RA, Hissa MN, Garber AJ, Luiz Gross J, Yuyan Duan R, Ravichandran S, et al.
The efficacy and safety of saxagliptin when added to metformin therapy in
patients with inadequately controlled type 2 diabetes with metformin alone.
Diabetes care 2009;32(9):1649-55.
50. DeFronzo RA, et al. Once-Daily Saxagliptin Added to Metformin Provides Sustained
Glycemic Control and Is Well Tolerated Over 102 Weeks in Patients With Type 2
Diabetes. Diabetes care 2009;58 (Suppl 1):A147, Abstract 547.
51. Goke B, Gallwitz B, Eriksson J, Hellqvist A, Gause-Nilsson I. Saxagliptin is non-inferior
to glipizide in patients with type 2 diabetes mellitus inadequately controlled on
metformin alone: a 52-week randomised controlled trial. International journal of
clinical practice 2010;64(12):1619-31.
52. Scheen AJ, Charpentier G, Ostgren CJ, Hellqvist A, Gause-Nilsson I. Efficacy and
safety of saxagliptin in combination with metformin compared with sitagliptin in
combination with metformin in adult patients with type 2 diabetes mellitus. Diabetes/
metabolism research and reviews 2010;26(7):540-9.
53. Pfutzner A, Paz-Pacheco E, Allen E, Frederich R, Chen R, Investigators CV. Initial
combination therapy with saxagliptin and metformin provides sustained glycaemic
control and is well tolerated for up to 76 weeks. Diabetes, obesity & metabolism
2011;13(6):567-76.
54. Chacra AR, et al. Saxagliptin added to a submaximal dose of sulphonylurea
improves glycaemic control compared with uptitration of sulphonylurea in patients
with type 2 diabetes: a randomised controlled trial. The International Journal of
Clinical Practice 2009;Published online - doi: 10.1111/j.1742-1241.2009.02143.x.
55. Hollander P, Li J, Allen E, Chen R. Saxagliptin added to a thiazolidinedione improves
glycemic control in patients with type 2 diabetes and inadequate control on
thiazolidinedione alone. The Journal of clinical endocrinology and metabolism
2009;94(12):4810-9.
56. DeFronzo RA, Fleck PR, Wilson CA, Mekki Q. Efficacy and safety of the dipeptidyl
peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate
glycemic control: a randomized, double-blind, placebo-controlled study. Diabetes
care 2008;31(12):2315-7.
57. Nauck MA, Ellis GC, Fleck PR, Wilson CA, Mekki Q, Alogliptin Study G. Efficacy and
safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy
in patients with type 2 diabetes inadequately controlled with metformin mono
therapy: a multicentre, randomised, double-blind, placebo-controlled study. Inter-
national journal of clinical practice 2009;63(1):46-55.
58. Pratley RE, Kipnes MS, Fleck PR, Wilson C, Mekki Q, Alogliptin Study G. Efficacy and
safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes
inadequately controlled by glyburide monotherapy. Diabetes, obesity & metabolism
2009;11(2):167-76.
76